Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Karuna Therapeutics
2023 · Acquisition/Merger · $14.0B · Complete
Announcement Sentiment
75
Strongly positive
Outcome Score
76
Worked — the deal delivered on its rationale.
BMS acquired Karuna Therapeutics for $14B for schizophrenia treatment KarXT.
Key facts
- Announced Dec 22, 2023
- Closed Mar 18, 2024
- Deal value $14.0B
- Deal type Acquisition/Merger
- Therapeutic area Neurology
- Key assets KarXT
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals